Pirfenidone improves survival in IPF: results from a real-life study.

George A MargaritopoulosAthina TrachalakiAthol U WellsEirini VasarmidiEleni BibakiGeorge PapastratigakisStathis DetorakisNikos TzanakisKaterina M Antoniou

Published in: BMC pulmonary medicine (2018)

Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone.

Keyphrases

idiopathic pulmonary fibrosis
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
pulmonary fibrosis
prognostic factors
patient reported outcomes
smoking cessation
hiv infected